Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

PD-L1 antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (54) Apoptosis (3) Autophagy (1) CTLA-4 (2) DGK (1) Drug-Linker Conjugates for ADC (1) EGFR (1) IFNAR (1) LAG-3 (3) Toll-like Receptor (TLR) (3)
By Research Areas:	Cancer (54) Infection (1) Inflammation/Immunology (15)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Antibodies

Targets Recommended: PD-1/PD-L1 ADC Antibody Antibody-Drug Conjugates (ADCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)

PD-1/PD-L1 Inflammation/Immunology

Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse PD-L1 IgG2b antibody inhibitor derived from host rat.

*Anti-Mouse PD-L1/B7-H1 Antibody* (10F.9G2)**	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse *PD-L1* IgG2b antibody inhibitor derived from host rat.

HY-108730

Avelumab 5+ Cited Publications Anti-Human PD-L1, Human antibody; MSB 0010718C; MSB0010718C	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

HY-P99422

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal *PD-L1* (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .

HY-P9972

Spartalizumab PDR001	PD-1/PD-L1	Cancer
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds *PD-1* with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) .

HY-P99475

Betifisolimab MSB-2311	PD-1/PD-L1	Cancer
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .

HY-P5276

Human membrane-bound PD-L1 polypeptide

PD-1/PD-L1 Cancer

Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production .

Human membrane-bound PD-L1 polypeptide	PD-1/PD-L1	Cancer
Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce *PD-L1* antibody production .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to *PD-1, thereby blocking the interaction of PD-1* with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to *PD-L1. Garivulimab selectively blocks the interaction of PD-L1* and PD-1. Garivulimab has antitumor activity .

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- *PD-L1* antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .

HY-P99723

Manelimab

BCD-135
PD-1/PD-L1 Cancer

Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .

Manelimab BCD-135	PD-1/PD-L1	Cancer
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells .

HY-P9902A

Pembrolizumab (anti-PD-1) 2 Publications Verification	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* .

HY-P9919

Durvalumab 5 Publications Verification MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of *PD-L1* to both *PD-1* and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of *PD-L1* and *PD-1*. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .

HY-P9904

Atezolizumab Maximum Cited Publications 19 Publications Verification MPDL3280A	PD-1/PD-L1 Apoptosis Autophagy	Cancer
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-P99641

Gilvetmab

PD-1/PD-L1 Cancer

Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .

Gilvetmab	PD-1/PD-L1	Cancer
Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-P9971

Camrelizumab 1 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99419

Acasunlimab GEN1046	PD-1/PD-L1	Cancer
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting *PD-L1* and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-157937

VISTA-IN-3	IFNAR	Cancer
VISTA-IN-3 (Compound A4) is a potent VISTA small molecule inhibitor with a K_D value of 0.49 μM. VISTA-IN-3 can induce the release of IFN-γ cytokines. VISTA-IN-3 synergistically enhances anti-cancer activity with PD-L1 antibody .

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-138139A

AXC-715 hydrochloride T785 hydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology
AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 . AXC-715, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .

HY-138139B

AXC-715 trihydrochloride T785 trihydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology
AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 . AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against *PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1* pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-P99144

Anti-Mouse PD-1 Antibody (RMP1-14)

1 Publications Verification

PD-1/PD-L1 Inflammation/Immunology

Anti-Mouse PD-1 Antibody is an anti-mouse PD-1 IgG1 antibody inhibitor.
HY-P99457

Balstilimab

AGEN2034
PD-1/PD-L1 Inflammation/Immunology

Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 .
HY-P99106

Acrixolimab

PD-1/PD-L1 Cancer

Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .
HY-P9997

Rosnilimab

ANB030
PD-1/PD-L1 Cancer

Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .

Anti-Mouse PD-1 Antibody (RMP1-14) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody is an anti-mouse *PD-1* IgG1 antibody inhibitor.

Balstilimab AGEN2034	PD-1/PD-L1	Inflammation/Immunology
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against *PD-1* .

Acrixolimab	PD-1/PD-L1	Cancer
Acrixolimab a humanized IgG4-κ antibody, targeting to *PD-1* .

Rosnilimab ANB030	PD-1/PD-L1	Cancer
Rosnilimab is a humanized IgG1-κ antibody targeting to *PD-1* .

HY-108730A

Avelumab (anti-PD-L1) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (anti-PD-L1) is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity .

HY-P99679

Izuralimab

PD-1/PD-L1 Inflammation/Immunology Cancer

Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1 .

Izuralimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1 .

HY-P990014

Danburstotug IMC-001; STI-3031	PD-1/PD-L1	Inflammation/Immunology Cancer
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor *PD-1* antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-P9996

Reozalimab

LY3434172
PD-1/PD-L1 Cancer

Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research .

Reozalimab LY3434172	PD-1/PD-L1	Cancer
Reozalimab is a bispecific antibody targeting to *PD-1/PD-L1. Reozalimab mediates antibody*-dependent cell cytotoxicity in cancer research .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against *PD-1* that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-P99639

Geptanolimab APL-501; CBT-501; GB-226	PD-1/PD-L1	Cancer
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .

HY-W457085

PD-1/PD-L1-IN-29 intermediate-2	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 intermediate-2 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-48934

PD-1/PD-L1-IN-29 intermediate-1	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 intermediate-1 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-P99957

Zeluvalimab

AMG-404
PD-1/PD-L1 Cancer

Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer .

Zeluvalimab AMG-404	PD-1/PD-L1	Cancer
Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer .

HY-P99785

Opucolimab HLX20	PD-1/PD-L1	Cancer
Opucolimab is an *anti-PD-L1* recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .

HY-P99203

Cemiplimab	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4	Inflammation/Immunology
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P990035

Benmelstobart

PD-1/PD-L1 Cancer

Benmelstobart is an IgG1κ antibody targeting PD-L1/CD274, derived from mice .

Benmelstobart	PD-1/PD-L1	Cancer
Benmelstobart is an IgG1κ antibody targeting *PD-L1*/CD274, derived from mice .

HY-P9902

Pembrolizumab 5+ Cited Publications MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P99619

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .

HY-P9903

Nivolumab 15+ Cited Publications BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P99884

Sasanlimab

PF-06801591
PD-1/PD-L1 Others

Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Inflammation/Immunology Cancer
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and *PD-1* and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .

HY-P9993

Peresolimab LY-3462817	PD-1/PD-L1	Cancer
Peresolimab is a humanized IgG1-κ antibody targeting to *PD-1*. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis .

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

486 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 486 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Cat. No.	Product Name	Target	Research Area

HY-P5276

Human membrane-bound PD-L1 polypeptide

PD-1/PD-L1 Cancer

Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production .

Cat. No.	Product Name	Target	Research Area

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)

PD-1/PD-L1 Inflammation/Immunology

Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse PD-L1 IgG2b antibody inhibitor derived from host rat.